Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;10(5):1171-1173.
doi: 10.1111/jdi.13123. Epub 2019 Aug 20.

The journey to understanding incretin systems: Theory, practice and more theory

Daisuke Yabe  1   2   3 , Hitoshi Kuwata  2   4   5 , Yutaka Seino  2   4
Affiliations

The journey to understanding incretin systems: Theory, practice and more theory

Daisuke Yabe et al. J Diabetes Investig. 2019 Sep.

Abstract

Accumulating clinical data on incretin-based dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in the past decade have clearly confirmed their safety and efficacy as antidiabetes drugs. However, the journey to understand the incretin system and its role in health and disease continues.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The journey to understanding incretin systems in human and experimental models. Events in humans are labeled by blue; those in experimental models by pink. cDNA, complementary deoxyribonucleic acid; CVOTs, cardiovascular outcome trials; DPP‐4, dipeptidyl peptidase‐4; GIP, glucose‐dependent insulinotropic polypeptide; GIPR, glucose‐dependent insulinotropic polypeptide receptor; GLP‐1, glucagon‐like peptide‐1; GLP‐1R, GLP‐1 receptor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cho YM. Incretin physiology and pathophysiology from an Asian perspective. J Diabetes Investig 2015; 6: 495–507. - PMC - PubMed
    1. Seino Y, Kuwata H, Yabe D. Incretin‐based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig 2016; 7(Suppl 1): 102–109. - PMC - PubMed
    1. Seino Y, Fukushima M, Yabe D. GIP and GLP‐1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010; 1: 8–23. - PMC - PubMed
    1. Moore B. On the treatment of diabetus mellitus by acid extract of Duodenal Mucous Membrane. Biochem J 1906; 1: 28–38. - PMC - PubMed
    1. Yabe D, Seino Y, Seino Y. Incretin concept revised: the origin of the insulinotropic function of glucagon‐like peptide‐1 ‐ the gut, the islets or both? J Diabetes Investig 2018; 9: 21–24. - PMC - PubMed

MeSH terms

Substances